Ask AI
James A. Davis

James A. Davis, PharmD, BCOP

Clinical Pharmacy Specialist, Myeloma/Lymphoma
The Medical University of South Carolina, Hollings Cancer Center
Affiliate Assistant Professor
MUSC College of Pharmacy
Charleston, South Carolina

Explore Activities by James A. Davis

Title
Format
Credit Type
Credits
Optimizing Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Pharmacist Perspectives

Content Format:

Podcast

Credit Type:

--

Credits:

--
Advances in Smoldering and Transplant-Eligible Newly Diagnosed Multiple Myeloma: Risk Stratification, MRD-Guided Therapy, and Emerging Treatment Strategies

Content Format:

Text Module

Credit Type:

ACPE-P

Credits:

0.50
Advances in Smoldering and Transplant-Eligible Newly Diagnosed Multiple Myeloma: Risk Stratification, MRD-Guided Therapy, and Emerging Treatment Strategies

Content Format:

Slideset

Credit Type:

--

Credits:

--
Frontline Management of Transplant-Ineligible Multiple Myeloma: Optimizing Therapy, Supportive Care, and Patient Outcomes

Content Format:

Text Module

Credit Type:

ACPE-P

Credits:

0.50
Frontline Management of Transplant-Ineligible Multiple Myeloma: Optimizing Therapy, Supportive Care, and Patient Outcomes

Content Format:

Slideset

Credit Type:

--

Credits:

--
Individualizing Treatment Strategies in Multiple Myeloma: From Risk Assessment to Supportive Care

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
BCMA Has Moved Upstream—Managed Care Strategy Must Follow

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Optimizing Outcomes With Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Best Practices for Oncology Pharmacists #2 

Content Format:

Slideset

Credit Type:

--

Credits:

--
Optimizing Outcomes With Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Best Practices for Oncology Pharmacists

Content Format:

Slideset

Credit Type:

--

Credits:

--
Targeting BCMA in Early Relapsed/Refractory Myeloma: Translating New Clinical Evidence into Managed Care Strategies

Content Format:

Video

Credit Type:

ACPE

Credits:

1.50
Targeting BCMA in Early R/R Myeloma: Overview & CAR T-Cell Therapy

Content Format:

Slideset

Credit Type:

--

Credits:

--
Targeting BCMA in Early R/R Myeloma: Bispecific Antibodies and Antibody Drug Conjugates

Content Format:

Slideset

Credit Type:

--

Credits:

--
Targeting BCMA in Early R/R Myeloma: Considerations for Care Management

Content Format:

Slideset

Credit Type:

--

Credits:

--
BTK Inhibitors in CLL: Key Clinical Updates From ASCO & EHA 2025

Content Format:

Podcast

Credit Type:

--

Credits:

--
CLL Therapy Today: Answers to Your Latest Questions From the Experts

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Optimizing BTK Inhibitor Therapy in CLL: Updates and Strategies for Oncology Pharmacists

Content Format:

Video

Credit Type:

ACPE-P

Credits:

1.00
Optimizing BTK Inhibitor Therapy in CLL: Updates and Strategies for Oncology Pharmacists

Content Format:

Video

Credit Type:

ACPE-P

Credits:

1.00
Optimizing BTK Inhibitor Therapy in CLL: Updates and Strategies for Oncology Pharmacists

Content Format:

Slideset

Credit Type:

--

Credits:

--
Adverse Event Management, Adherence, and Drug–Drug Interactions With BTK Inhibitors

Content Format:

Slideset

Credit Type:

--

Credits:

--